+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 15Years - 45Years
FEMALE
ID07822321

Evaluating Oral LPCN 1154A Tablets Compared to Placebo for Treating Severe Postpartum Depression in Women Aged 15 to 45

Led by Lipocine Inc. · Updated on 2026-09-16

120

Participants Needed

16

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating LPCN 1154A as a possible treatment for postpartum depression PPD in women with severe symptoms. This phase 3 trial aims to find out if LPCN 1154A can reduce depressive symptoms and how well it is tolerated, including potential side effects. Participants receive either oral LPCN 1154A tablets or placebo tablets for 48 hours. The study is randomized and blinded to compare these two groups in parallel. The treatment phase lasts for 48 hours. During the study, participants will be assessed for changes in depression severity using the Hamilton Depression Rating Scale HAM-D from baseline to hour 60, along with other measures at hour 12 and day 30. Safety and side effects are monitored throughout. The participation spans from screening through treatment and follow-up assessments.

CONDITIONS

Brief Title

Brexanolone Lifting Outcomes Of Moms

Research Team

V

Vice President of Clinical Development

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here